NCT03768492View on ClinicalTrials.gov

Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Carcinoma Breast
Interventions
DRUG

Caffeine anhydrous 5% added to Lipoderm Cream Base.

Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm

OTHER

Lipoderm Cream Base

Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm

Trial Locations (1)

10016

New York University Medical Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER